Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10484625 | Value in Health | 2014 | 11 Pages |
Abstract
Although the cost-effectiveness of omalizumab is more favorable under the PAS price, it represents good value for money only in severe subgroups and under optimistic assumptions regarding asthma mortality and improvement in health-related quality of life. For these reasons, omalizumab should be carefully targeted to ensure value for money.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Rita MSc, Claire PhD, Stephen Prof,